Impact of Dual Antiplatelet Therapy Duration on Bleeding and Ischemic Events Following Percutaneous Coronary Intervention with Drug-Coated Balloons: A Meta-Analysis

Category	Detail
Condition	Coronary Artery Disease (CAD)
Key Mechanisms	Dual antiplatelet therapy (DAPT) duration impacts bleeding and ischemic outcomes post-PCI with drug-coated balloons (DCB).
Target Population	Adult patients undergoing PCI with DCB for de novo lesions or in-stent restenosis.
Care Setting	Cardiology departments performing percutaneous coronary interventions.

Current guidelines recommend a minimum of 6 months DAPT for DES and at least 12 months for ACS.
DCB offers a 'leave nothing behind' strategy, reducing risks associated with metallic stents.
Optimal DAPT duration after DCB remains poorly defined, with emerging data suggesting shorter regimens may be safe.
Meta-analysis aimed to evaluate DAPT duration and its association with bleeding and ischemic outcomes.
Study quality assessed using Cochrane Collaboration and PRISMA guidelines.

Consider DAPT duration based on individual patient risk factors and clinical scenarios.

Monitor for bleeding and ischemic events post-PCI, especially in high bleeding risk patients.

Evaluate risks of late thrombosis, malapposition, and underexpansion associated with stent use.

Adults undergoing PCI with DCB for CAD.

DAPT duration varies; emerging evidence suggests shorter regimens may minimize bleeding without compromising ischemic protection.

Adhere to current guidelines for DAPT duration in DES while considering emerging evidence for DCB.
Utilize a patient-centered approach to determine DAPT duration based on individual risk profiles.

Clinical Scorecard: Impact of Dual Antiplatelet Therapy Duration on Bleeding and Ischemic Events Following Percutaneous Coronary Intervention with Drug-Coated Balloons: A Meta-Analysis